

Special Issue

The Health Economic Value of Vaccines

Message from the Guest Editors

The health economic value of vaccines has received increasing attention over the last couple of years due to the COVID-19 pandemic, but is not always comprehensively understood for other non-COVID vaccines. Alleviating (seasonal) capacity pressure on healthcare systems, keeping young as well as elderly populations as healthy as possible, tackling antimicrobial resistance, and maintaining a healthy and productive workforce are just a few examples of the broader healthcare and societal impacts of vaccination programs. Health economic evaluation plays a key role in quantifying the broader value of vaccines to inform healthcare policy and resource allocation decisions, and its methods are evolving. This Special Issue aims to provide an overview of the recent developments in this area from theoretical, methodological, and practical (illustrations) angles.

Guest Editors

Prof. Dr. Lotte Steuten

1. Office of Health Economics, London SW1E 6QT, UK
2. City Health Economics Centre (CHEC), City, University of London, London EC1V 0HB, UK

Prof. Dr. Maarten J. Postma

Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands

Deadline for manuscript submissions

closed (31 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/164962

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).